These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 20005378)

  • 1. The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C.
    Ikegami T; Taketomi A; Soejima Y; Yoshizumi T; Fukuhara T; Kotoh K; Shimoda S; Kato M; Maehara Y
    Transplant Proc; 2009 Dec; 41(10):4246-52. PubMed ID: 20005378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.
    Ueda Y; Marusawa H; Kaido T; Ogura Y; Oike F; Mori A; Ogawa K; Yoshizawa A; Hatano E; Miyagawa-Hayashino A; Haga H; Egawa H; Takada Y; Uemoto S; Chiba T
    J Viral Hepat; 2012 Jan; 19(1):32-8. PubMed ID: 21129128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation.
    Ueda Y; Takada Y; Haga H; Nabeshima M; Marusawa H; Ito T; Egawa H; Tanaka K; Uemoto S; Chiba T
    Transplantation; 2008 Mar; 85(6):855-62. PubMed ID: 18360268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response.
    Jiménez-Pérez M; Sáez-Gómez AB; Pérez-Daga JA; Lozano-Rey JM; de la Cruz-Lombardo J; Rodrigo-López JM
    Transplant Proc; 2010 Mar; 42(2):666-8. PubMed ID: 20304219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.
    Lodato F; Berardi S; Gramenzi A; Mazzella G; Lenzi M; Morelli MC; Tame MR; Piscaglia F; Andreone P; ; Ballardini G; Bernardi M; Bianchi FB; Biselli M; Bolondi L; Cescon M; Colecchia A; D'Errico A; Del Gaudio M; Ercolani G; Grazi GL; Grigioni W; Lorenzini S; Pinna AD; Ravaioli M; Roda E; Sama C; Vivarelli M
    Aliment Pharmacol Ther; 2008 Aug; 28(4):450-7. PubMed ID: 18549463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combined interferon-alfa-2b and ribavirin therapy in patients with recurrent chronic hepatitis c after liver transplantation].
    Lengyel G; Kóbori L; Fehérvári I; Nemes B; Görög D; Patonai A; Sárváry E; Varga M; Perner F; Fehér J
    Orv Hetil; 2003 Nov; 144(48):2367-70. PubMed ID: 14753031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
    Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
    Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
    Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
    Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatitis C virus infection in patients of northern India.
    Hazari S; Panda SK; Gupta SD; Batra Y; Singh R; Acharya SK
    J Gastroenterol Hepatol; 2004 Sep; 19(9):1058-65. PubMed ID: 15304125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation.
    Yedibela S; Schuppan D; Müller V; Schellerer V; Tannapfel A; Hohenberger W; Meyer T
    Liver Int; 2005 Aug; 25(4):717-22. PubMed ID: 15998420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
    Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
    Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
    Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
    J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
    Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.